Physician profile
John D Wulff
NPI 1477530913
$141,575.73
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $20K · 2021: $54K · 2022: $32K · 2023: $714 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37,144.76 | 2021 | |
| Acorda Therapeutics, INC | $27,871.01 | 2019-2023 | Ampyra, Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $25,603.21 | 2022 | |
| Adamas Pharmaceuticals, INC. | $18,300.87 | 2019-2021 | |
| Allergan, INC. | $15,936.20 | 2020-2021 | |
| Abbvie INC. | $13,440.90 | 2020-2024 | Ubrelvy, Qulipta |
| Mdd US Operations, LLC | $659.88 | 2019-2023 | Apokyn |
| Acadia Pharmaceuticals INC | $193.67 | 2019-2024 | Nuplazid |
| Eisai INC. | $188.52 | 2022-2023 | |
| Lilly USA, LLC | $162.99 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Novartis Pharmaceuticals Corporation | $157.86 | 2019-2023 | |
| Ucb, INC. | $150.82 | 2019-2024 | Briviact |
| Chiesi USA, INC. | $139.83 | 2020-2021 | |
| Neurelis, INC. | $110.20 | 2020-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $92.66 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wulff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.